Literature DB >> 1906778

Pharmacodynamics of mitomycin C in cultured human bladder tumors.

T D Schmittgen1, M G Wientjes, R A Badalament, J L Au.   

Abstract

The effects of mitomycin C (MMC) concentration and exposure time on the inhibition of tumor cell labeling index (LI) were studied using surgical bladder tumor samples from 14 patients. The bladder tumors were cultured as 1-mm3 fragments on collagen gels. LI was determined by incorporation of [3H]thymidine and autoradiography. All tumors responded to MMC. However, the sensitivity varied significantly between tumors. At a 2-h exposure, the concentrations required for 50 and 90% inhibition (IC50 and IC90) ranged from 0.237 to 14.9 and 2.76 to 74.5 micrograms/ml, respectively. There was an inverse correlation between MMC activity and tumor LI; the IC values were higher for the more rapidly proliferating tumors. Exposure time had a pronounced effect on MMC activity. Shortening the exposure time from 2 to 0.5 h increased the IC50 3-fold, while prolonging the exposure time from 2 to 24 h decreased the IC50 6-fold. To determine the minimum concentration and exposure time necessary to reduce tumor LI by 90%, the data for 6 tumors were computer fitted to the pharmacodynamic relationship Cn x T = k. The analysis showed that, on average, a 2.5-h exposure of 3 micrograms/ml was needed for 50% inhibition and a 7-h exposure of 8 micrograms/ml was needed for 90% inhibition. A comparison of the IC values of MMC determined in this study with the literature values determined using monolayer and spheroid cultures of established human bladder tumor cell lines showed that the drug activity in cultured tumor fragments ranged from 7- to 5300-fold lower than that in established cell lines. In summary, our data demonstrate a heterogeneity in the response of bladder tumors from individual patients to MMC, a decreased sensitivity to MMC with increasing tumor proliferation, and that drug concentration and exposure time are critical determinants of MMC activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906778

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Long-term passage of human tissues in vitro as three-dimensional histolines.

Authors:  H K Slocum; K Tòth; L Li; S G Chang; R M Hoffman; Y M Rustum
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

Review 2.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  Accuracy and precision of pharmacodynamic exponent.

Authors:  N J Millenbaugh; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

4.  Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.

Authors:  T D Schmittgen; A Koolemans-Beynen; T E Webb; T J Rosol; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Analyzing the effects of instillation volume on intravesical delivery using biphasic solute transport in a deformable geometry.

Authors:  Sean G Smith; Boyce E Griffith; David A Zaharoff
Journal:  Math Med Biol       Date:  2019-06-13       Impact factor: 1.854

6.  Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.

Authors:  W C Yen; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

7.  Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.

Authors:  Savino Mauro Di Stasi; Claus Riedl
Journal:  World J Urol       Date:  2009-02-21       Impact factor: 4.226

8.  Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.

Authors:  J R Weaver; Y Gan; J L Au
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

9.  Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.

Authors:  M G Wientjes; R A Badalament; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Histocultures of patient head and neck tumors for pharmacodynamics studies.

Authors:  J L Au; M G Wientjes; T J Rosol; A Koolemans-Beynen; E A Goebel; D E Schuller
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.